A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Saved in:
| Title: | A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. |
|---|---|
| Authors: | Ma CX; Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, Campus Box 8056, 660 South Euclid Avenue, St. Louis, MO 63110, USA. cma@dom.wustl.edu, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM, Picus J, Creekmore AN, Mwandoro T, Yarde ER, Reed J, Ebbert M, Bernard PS, Watson M, Doyle LA, Dancey J, Piwnica-Worms H, Fracasso PM |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2013 Jan; Vol. 137 (2), pp. 483-92. Date of Electronic Publication: 2012 Dec 15. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
